Stock VCYT VERACYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
21.29 USD +1.96% Intraday chart for Veracyte, Inc. 0.00% -22.61%
Jun. 03 Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors CI
May. 07 Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
BU
Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
CI
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
BU
Veracyte to Participate in Upcoming Investor Conferences
BU
Veracyte: Q1 Earnings Snapshot
AQ
Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M
MT
Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024
Veracyte Announces First Quarter 2024 Financial Results
BU
Veracyte, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024
CI
Veracyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024
CI
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
BU
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression among Patients Undergoing Active Surveillance
AQ
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
BU
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
BU
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
BU
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating
MT
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
BU
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating
MT
Sector Update: Health Care Stocks Mixed Premarket Friday
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VCYT Stock
  4. News Veracyte, Inc.